Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors

NCT00470613 is registered in ClinicalTrials.gov with SynerGene Therapeutics, Inc. as lead sponsor.

NCT NCT00470613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00470613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Safety and Pharmacokinetic Study of Escalating Doses of SGT-53 for Infusion in Subjects With Advanced Solid Tumors
Lead sponsor
SynerGene Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2008
Completion date
December 31, 2016
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm